Pacritinib – is it safe for treating MF?
Ruben A. Mesa
Overview of new combinaton therapies in acute myeloid leukemia (AML)
Naval G. Daver
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
Highlights of ASH in CLL
John Gribben et al.
Current research into JAK inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
Haifa Kathrin Al-Ali